A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 84
Summary
- Conditions
- Fallopian Tube Cancer
- Cervical Cancer
- Colorectal Cancer
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Hepatocellular Carcinoma (HCC)
- Melanoma
- Primary Peritoneal Cancer
- Microsatellite Instability-high or Mismatch Repair Deficient (MSI-H/dMMR)
- Renal Cell Carcinoma (RCC)
- Urothelial Neoplasm
- Serous Epithelial Ovarian Cancer
- Neoplasms
- Platinum-resistant Ovarian Cancer (PROC)
- Non - Small Cell Lung Cancer NSCLC
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03311334
- Collaborators
- Not Provided
- Investigators
- Not Provided